Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • May 2021
  • Article
  • AEA Papers and Proceedings

Private and Social Returns to R&D: Drug Development and Demographics

By: Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou and Joshua Krieger
  • Format:Print
  • | Pages:5
ShareBar

Abstract

Investment in intangible capital such as R&D has increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer products such as pharmaceutical drugs with limited spillovers to productivity. We document that a significant share of R&D spending in the United States is done by pharmaceutical firms and geared to developing drugs for older patients. Increased life expectancy and quality of life for the elderly increases welfare but may not be reflected in estimates of total factor productivity.

Keywords

Drug Development; Research and Development; Investment Return; Demographics; Pharmaceutical Industry

Citation

Benmelech, Efraim, Janice Eberly, Dimitris Papanikolaou, and Joshua Krieger. "Private and Social Returns to R&D: Drug Development and Demographics." AEA Papers and Proceedings 111 (May 2021): 336–340.
  • Find it at Harvard
  • Register to Read

About The Author

Joshua Lev Krieger

Entrepreneurial Management
→More Publications

More from the Authors

    • March 2022
    • Faculty Research

    Tomorrow.io Goes To Space

    By: Joshua Lev Krieger, Abhishek Nagaraj and James Barnett
    • March 2022
    • Faculty Research

    Biobot Analytics

    By: Ray Kluender, Joshua Krieger and Mitch Weiss
    • 2022
    • Review of Financial Studies

    Missing Novelty in Drug Development

    By: Joshua Krieger, Danielle Li and Dimitris Papanikolaou
More from the Authors
  • Tomorrow.io Goes To Space By: Joshua Lev Krieger, Abhishek Nagaraj and James Barnett
  • Biobot Analytics By: Ray Kluender, Joshua Krieger and Mitch Weiss
  • Missing Novelty in Drug Development By: Joshua Krieger, Danielle Li and Dimitris Papanikolaou
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Digital Accessibility
Copyright © President & Fellows of Harvard College